期刊
CHINA CDC WEEKLY
卷 3, 期 14, 页码 291-297出版社
Chinese Center for Disease Control and Prevention
DOI: 10.46234/ccdcw2021.068
关键词
-
资金
- Ministry of Science and Technology of China [2017ZX10201101, 2018ZX10721102-006]
- National Natural Science Foundation of China [11971479]
This report highlights the association between HIV drug resistance and increased risk of death among HIV-infected patients receiving ART, emphasizing the importance of strengthening drug resistance monitoring and prevention during ART treatment. Routine and prompt viral load testing and drug resistance testing should be carried out for HIV-infected patients.
What is already known about this topic? With increasing coverage of antiretroviral therapy (ART) for HIV-infected patients, more and more attention has been paid to the impact of HIV drug resistance on death in those patients in China. What is added by this report? Among HIV-infected patients receiving ART, the risk of death is higher in patients with HIV drug resistance [adjusted odds ratio (AOR)=4.25, 95% confidence interval (CI): 2.10-8.64, with viral load >1,000 copies/mL but drug resistance untested (AOR=4.65, 95% CI: 1.74-12.39), and with neither viral load nor drug resistance being tested (AOR=17.52, 95% CI: 8.73-35.19) when compared with drug-sensitive patients. What are the implications for public health practice? It is important to strengthen drug resistance monitoring and prevention in HIV-infected patients. While performing ART for HIV-infected patients, viral load testing and drug resistance testing should be carried out routinely and promptly.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据